Nori Yumoto

Nori Yumoto has been working in the field of bioengineering since 2009. In 2009, they began their career as a Research Scientist (Molecular Neurobiology) at NYU Langone Medical Center, where they conducted research to understand the mechanisms of neuromuscular synapse formation and pathology of neurodegenerative diseases focusing on ALS. Her research findings were published in Nature journal. In 2017, Nori joined AstraZeneca as an Associate Medical Affairs Manager. In 2018, they joined Jiksak Bioengineering, Inc. as Co-Chief Executive Officer and Chief Technology Officer. In this role, they are responsible for selling their motor neuron device and discovering new therapeutics for ALS. The motor neurons are derived from iPS cells and are cultured on the original device to allow the cells to grow their axons longer and to form the axon bundles, which reflects more in vivo environments. Nori is also developing drug screen systems to find novel therapeutics for ALS by stabilizing the neuromuscular synapse.

Nori Yumoto obtained a Doctor of Philosophy (Ph.D.) in Medical Sciences, Molecular Biology, and Developmental Biology from Kyoto University between 2002 and 2008. Additionally, Nori Yumoto obtained The National License of Medical Technologist in Japan from the National (Japan) in March of 2002.